B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $110 to $125.